News

Nasdaq5mon
Atossa Therapeutics Provides Shareholder Update on Progress and Future Plans for (Z)-Endoxifen in Breast Cancer Treatment - Nasdaq
Atossa Therapeutics updates shareholders on clinical progress, ... In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCβ1, ...
Yahoo Finance2y
Atossa to Present a Trial in Progress Poster on its Neoadjuvant Breast Cancer Phase 2 Clinical Trial, EVANGELINE, at the 2023 American Society of Clinical ... - Yahoo Finance
SEATTLE, May 09, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant ...
Yahoo Finance1mon
Olema Oncology Announces Palazestrant Dose Selection and Trial-in-Progress Poster at ASCO 2025 Annual Meeting - Yahoo Finance
90 mg once-daily palazestrant dose selected for Part 2 of the Phase 3 OPERA-01 monotherapy trial and for the Phase 3 OPERA-02 combination trial with ribociclibOPERA-01 trial-in-progress poster to ...